John P Phd Longenecker

CIK 1288231 · President and CEO · last filed 2022-03-07

John P Phd Longenecker is a President and CEO who has filed 30 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for PCRX, was dated Mar 7, 2022. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $684.8K across reported positions. 26 SEC filings were submitted jointly with Pacira BioSciences, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$684.8K

Companies

Total Filings

Lifetime Open-Market Net

-$1.88M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

PCRX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

10445 PACIFIC CENTER CT
SAN DIEGO, CA 92121

Related Filers

Pacira BioSciences, Inc. — 26 joint filings, latest 2022-03-07

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
PCRX	Director	18,823	$36.38	$684.8K	-$1.90M	24	2022-03-07
Rein Therapeutics, Inc. (ALRN) Delisted	President and CEO	500	$2.11	$1.1K	$24.5K	2	2018-08-14
MMRGlobal, Inc. (FVRL) Delisted	President & CEO	178,560	—	—	$0	2	2008-05-08

Recent Filings

30 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2022-03-07	PCRX	Mixed	—	-$426.5K	EDGAR
2021-06-11	PCRX	Grant (A)	+1,066	$0	EDGAR
2021-03-03	PCRX	Mixed	—	-$291.4K	EDGAR
2020-06-11	PCRX	Grant (A)	+1,260	$0	EDGAR
2020-03-16	PCRX	Exer (M)	+3,736	$6.0K	EDGAR
2019-12-04	PCRX	Mixed	+2,700	-$53.5K	EDGAR
2019-06-06	PCRX	Grant (A)	+4,134	$0	EDGAR
2018-08-14	Rein Therapeutics, Inc. (ALRN) Delisted	Buy (P)	+10,000	$24.5K	EDGAR
2018-06-15	PCRX	Grant (A)	+782	$0	EDGAR
2018-05-17	Rein Therapeutics, Inc. (ALRN) Delisted	Grant (A)	—	$0	EDGAR

Showing 1–10 of 30

Page 1 of 3 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.